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AbstrACt
Objectives Guidelines recommending 12-month 
dual antiplatelet therapy (DAPT) in patients with ST-
elevation acute coronary syndrome (STEACS) undergoing 
percutaneous coronary intervention (PCI) were published in 
year 2012. We aimed to describe the influence of guideline 
implementation on the trend in 12-month persistence 
with DAPT between 2010 and 2015 and to evaluate its 
relationship with DAPT duration regimens recommended 
at discharge from PCI hospitals.
Design Observational study based on region-wide registry 
data linked to pharmacy billing data for DAPT follow-up.
setting All PCI hospitals (10) belonging to the acute 
myocardial infarction (AMI) code network in Catalonia 
(Spain).
Participants 10 711 STEACS patients undergoing PCI 
between 2010 and 2015 were followed up.
Primary and secondary outcome measures Primary 
outcome was 12-month persistence with DAPT. Calendar 
year quarter, publication of guidelines, DAPT duration 
regimen recommended in the hospital discharge report, 
baseline patient characteristics and significant interactions 
were included in mixed-effects logistic regression based 
interrupted time-series models.
results The proportion of patients on-DAPT at 12 months 
increased from 58% (56–60) in 2010 to 73% (71–75) 
in 2015. The rate of 12-month persistence with DAPT 
significantly increased after the publication of clinical 
guidelines with a time lag of 1 year (OR=1.20; 95% CI 1.11 
to 1.30). A higher risk profile, more extensive and complex 
coronary disease, use of drug-eluting stents (OR=1.90; 
95% CI 1.50 to 2.40) and a 12-month DAPT regimen 
recommendation at discharge from the PCI hospital 
(OR=5.76; 95% CI 3.26 to 10.2) were associated with 
12-month persistence.
Conclusion Persistence with 12-month DAPT has 
increased since publication of clinical guidelines. Even 
though most patients were discharged on DAPT, only 73% 
with potential indication were on-DAPT 12 months after 
PCI. A guideline-based recommendation at PCI hospital 
discharge was highly associated with full persistence with 
DAPT. Establishing evidence-based, common prescribing 
criteria across hospitals in the AMI-network would favour 
adherence and reduce variability.
IntrODuCtIOn
The need of dual antiplatelet therapy (DAPT) 
combining aspirin and an ADP-receptor 
blocker for at least 12 months in patients 
with ST-elevation acute coronary syndrome 
(STEACS) undergoing percutaneous coro-
nary intervention (PCI) is well established 
and was incorporated into clinical guidelines 
in 2012.1 2 
Adherence of patients to this strategy is 
crucial to ensure its efficacy. Adherence to 
strengths and limitations of this study
 ► The study describes the trends in persistence with 
dual antiplatelet therapy (DAPT) during 2010–2015 
in a region-wide comprehensive cohort of patients 
using administrative data linked to a clinical registry.
 ► It also evaluates the impact of the DAPT duration 
recommended at the percutaneous coronary inter-
vention hospital discharge on 12-month persistence.
 ► Limitations of using observational registry data in-
clude the possibility of coding errors and the inability 
to accurately identify specific contraindications for 
treatment or other patient characteristics that might 
be relevant for the study aims.
 ► The use of pharmacy refill data as a proxy of pa-
tients’ adherence and persistence has also limita-
tions which have been extensively described.
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medication is usually defined3 as the extent to which 
patients take medications as prescribed by their healthcare 
providers and persistence is defined as time from initia-
tion to discontinuation of a therapy. Patients’ persistence 
with DAPT may be influenced by several factors but will 
depend strongly on whether they ultimately receive a 
correct prescription from their physicians in the primary 
care setting. Patients may receive recommendations 
from various health providers at different stages of their 
process of care, from the interventionist cardiologist to 
their primary physician. It could be hypothesised that the 
last would tend to rely on the recommendation of the 
more specialised health professional. Thus, one poten-
tial determinant of patients’ persistence with DAPT for 
at least 12 months is the instructions provided in the 
discharge report of the hospital where the patient was 
attended during the acute phase.
In Catalonia, an autonomous region of Spain, the 
acute care of STEACS is organised through a region-wide 
network, the acute myocardial infarction (AMI) code, to 
derive patients with suspected STEACS to 1 of the 10 refer-
ence hospitals with PCI capability. Performance of the 
AMI code is prospectively and exhaustively registered,4 5 
providing an appropriate tool for quality evaluation. The 
Catalan Health Information System systematically regis-
ters, among other, data on pharmacy refills. Pharmacy 
billing data, although indirect, is an accepted method 
for evaluating persistence with treatment in large patient 
cohorts.3 6
The aims of the present study were, first, to describe 
persistence with DAPT for at least 12 months in patients 
with STEACS undergoing PCI from 2010 to 2015; second, 
to evaluate the influence guidelines recommendation 
for a 12-month DAPT schedule on the rate of 12-month 
persistence along time; and third, to evaluate the asso-
ciation of the DAPT duration recommended at the PCI 
hospital discharge with patients’ persistence with treat-
ment for at least 12 months.
MethODs
Data sources
Data were obtained through the Public Data Analysis for 
Health Research and Innovation Programme (PADRIS). 
The PADRIS allows access to information from different 
sources on public healthcare resources usage for the 
population of Catalonia linked at the patient level with 
warranted accomplishment of ethical principles. Specifi-
cally, for the present study we linked data of the pharmacy 
billing registry with the AMI code registry. The AMI code 
registry was launched in 2010 to evaluate performance of 
the AMI code.4 5 Exhaustiveness and quality of data are 
assessed periodically (see online supplementary methods 
for details). The database belongs to the Catalan Depart-
ment of Health and includes demographic, clinical and 
therapeutic data for each episode of hospitalisation for 
STEACS. It conforms to the ethical and legal require-
ments for research purposes.
The registry was completed for the purpose of the 
present analysis with retrospective collection of addi-
tional specific data: diseased vessels, responsible vessel, 
stent type and number of stents. The recommendation 
of antithrombotic drugs was also collected ad hoc for the 
study from the discharge report. The recommendation of 
DAPT was defined as the recommendation of acetylsali-
silic acid (ASA) and clopidogrel, prasugrel or ticagrelor 
for specified periods. If the recommended duration of 
DAPT was not specified, the discharge recommendation 
pattern was classified as ‘unspecified’. A local investigator 
at each centre performed the specific retrospective data 
collection.
History of major haemorrhage, neoplasia, renal 
disease, heart failure, peripheral arterial disease and 
atrial fibrillation, were obtained from minimum basic 
data set diagnoses coded in hospitalisation episodes 
occurring in the previous 3 months before index hospi-
talisation. Major haemorrhage was defined as: a diagnosis 
of digestive bleeding in any diagnostic position (primary 
or secondary) together with a procedure code for endo-
scopic treatment or for transfusion of blood products, 
or a diagnosis of haemorrhagic stroke, or a diagnosis of 
intraocular haemorrhage, or a diagnosis of other types of 
haemorrhage together with a procedure code for trans-
fusion of blood products. Major ischaemic events (AMI 
or stroke) and major haemorrhage during the 12 months 
following the index episode were obtained in the same 
way. Mortality during the 12 months following the index 
episode was obtained from the insured registry status.
Drug treatment during the 12-month postdischarge 
follow-up was obtained from the pharmacy billing registry. 
International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-MC) and ATC codes used 
for the identification of study variables are listed in the 
online supplementary tables 1 and 2.
Data availability statement
Additional data are not available due to ethical require-
ments of the PADRIS.
study population
We included all consecutive patients who survived a 
STEACS between January 2010 and December 2015, 
received primary or postfibrinolysis PCI in 1 of the 10 
reference hospitals of the AMI code network, were 
discharged home or transferred to another hospital and 
survived at least 1 month after AMI. New episodes of 
STEACS occurring to the same patients during the study 
period were only accounted as follow-up events. Patients 
with likely contraindication for DAPT (history of major 
bleeding or neoplasm in the 3 months prior to the index 
episode and patients requiring anticoagulation) were 
excluded.
Persistence with treatment
DAPT was defined as the concomitant use of ASA and a 
P2Y12 antagonist. Persistence with DAPT was estimated by 
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identification of consecutive months with pharmacy refills 
with one container of each agent in the 12-month period 
after hospital discharge. Because pharmacy billing is regis-
tered in a monthly basis and the exact day of dispensation 
is unknown, we considered that a monthly dispensation 
until at least month 11 after the index episode would 
approximate a 12-month treatment period. If more than 
one container were dispensed in 1 month, the excess 
containers were pulled along the following months. 
Non-persistence was defined as either discontinuation 
or a break in therapy of at least 2 months after pulling 
along the excess containers. To describe persistence over 
the whole study period, we estimated the proportion of 
patients alive and within the 12 months after discharge 
window who were on treatment on each month.7
The primary outcome was a patient’s persistence with 
DAPT for 12 months following discharge (or in other 
words, patients withdrawing both agents from the phar-
macy until at least month 11).
statistical analysis
We compared baseline characteristics between patients 
persisting with DAPT for at least 12 months and patients 
withdrawing DAPT before 12 months with χ2 test or t-test 
when appropriate. We tested for trends in patients’ char-
acteristics along calendar year of discharge for the index 
procedure with Jonckheere-Terpstra test for differences 
between ordered categories.
To evaluate the influence of time, guidelines publica-
tion and the DAPT duration recommended in the PCI 
hospital discharge report, we modelled logistic regres-
sion based interrupted time-series analysis,8 adjusting 
for baseline characteristics. As a first step, because it is 
expected that guidelines publication influences practice 
with a time delay, we plotted the proportion of patients 
persisting on-DAPT for 12 months by year quarter of 
discharge from the PCI hospital and we tested models 
with a slope change (indicating the start of guideline 
implementation) at different lag periods after publication 
of the European clinical guidelines (last quarter of 2012). 
Once the lag period between guidelines publication and 
implementation of recommendations was estimated, we 
included patient characteristics and second or third level 
interactions of each characteristic with year quarter and 
moment of implementation. We also included an auto-
correlation term. We coded time (T) as the time elapsed 
since the publication of guidelines plus the lag period 
(in quarters) and a dummy variable (Xt) indicating the 
preimplementation period (coded 0) or the postimple-
mentation period (coded 1).9
The standard model specification was the following:
  logit
(
Yt
)
= β0 + β1T + β2Xt + β3TXt   
Where  β0  represents the baseline level at T = 0,  β1  is 
interpreted as the change in outcome associated with a 
time unit (quarter) increase (representing the under-
lying preimplementation trend),  β2  is the level change 
following the implementation and  β3  indicates the slope 
change following the implementation (using the interac-
tion between time and implementation: TXt). Additional 
terms can be added to model the effect of other covaria-
bles and their interactions with T and Xt and to include 
random effects. Note that we set T = 0 at the quarter 
where we observed a significant change in the slope at a 
lag time after guidelines publication.
We took into account the clustered structure of data 
with patients being treated and, most importantly, with 
recommendations on DAPT duration being provided in 
different hospitals, by introducing random effects in the 
logistic regression models.
We tested whether models including random intercepts 
for hospital and random slopes for each independent 
variable were significant using a deviance-based test of 
hypothesis.
Variable selection for multilevel modelling was based 
on the bivariate associations with the rate of each depen-
dent variable. Candidate individual variables were those 
described in tables 1 and 2. We retained in the final 
model all variables with a p value <0.2.
Plots of predicted probability values were used to show 
marginal effects of variables of interest and variability 
between centres.
sensitivity analyses
Because a substantial proportion of patients were 
returned to their reference hospital and because it was 
unknown whether the DAPT duration recommendation 
was changed at discharge from the second hospital, we 
performed sensitivity analyses excluding these patients. 
Additionally, because ischaemic and haemorrhagic 
events occurring during follow-up would change the 
treatment length, sensitivity analyses were also performed 
by excluding patients suffering any vascular event during 
follow-up.
Patient and public involvement
Neither patients nor public were directly involved in the 
study.
results
After excluding patients with likely contraindication 
for DAPT (figure 1), we identified 10 711 STEACS 
patients undergoing PCI who were potential candidates 
to receive DAPT for at least 12 months and survived for 
at least 1 month after discharge. Six hundred and thir-
ty-one (5.9%) patients experienced an ischaemic major 
event (AMI or stroke) within 12 months after the index 
episode, 100 (0.9%) had a major haemorrhage and 280 
(2.6%) died between 1 and 12 months after the index 
episode. After excluding patients who died or were lost to 
follow-up and patients with errors in quarter allocations, 
10 262 patients remained for analysis.
Table 1 shows characteristics of study patients 
depending on persistence with DAPT. Patients persisting 
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for at least 12 months had higher prevalence of cardio-
vascular risk factors (hypertension, diabetes and hyper-
cholesterolaemia), higher rate of a previous history 
of cardiovascular disease, more extended coronary 
disease, higher rate of drug-eluting stents implantation 
and slightly higher ischaemic risk (as measured with 
the DAPT score10). Persisting patients were more often 
transferred to their reference hospital and had had a 
prescription for a longer DAPT period at discharge 
from the PCI hospital.
The rate of patients on-DAPT after discharge from the 
PCI hospital was 91% (95% CI 90 to 91) without relevant 
differences between years (online supplementary figure 
1). The proportion of patients on-DAPT at 12 months 
significantly increased from 58% (56–61) in 2010 to 
73% (71–75) in 2015. The larger increase in 12-month 
persistence was observed between 2014 (64% (62–66)) 
and 2015, 2 years after the publication of clinical guide-
lines. The proportion of patients with prasugrel or tica-
grelor instead of clopidogrel started increasing after 2012 
(online supplementary figure 2).
Some baseline characteristics showed a temporal trend 
over the study period 2010–2015 (table 2). The prev-
alence of cardiovascular risk factors (smoking, hyper-
tension and hypercholesterolaemia) and comorbidities 
increased slightly. Likewise, the number of treated vessels 
Table 1 Characteristics of study patients according to DAPT persistence during follow-up
DAPT <12 months
(n=3684)
DAPT ≥12 months
(n=6578)
Total
(n=10 262)
P valueN n (%) N n (%) N n (%)
Age 3684 61.19±13.21 6578 61.18±12.38 10 262 61.19±12.69 0.578
Gender (female) 3684 765 (20.8%) 6578 1319 (20.1%) 10 262 2084 (20.3%) 0.399
Smoke (Y) 3684 1774 (48.2%) 6578 3042 (46.2%) 10 262 4816 (46.9%) 0.064
Hypertension (Y) 3684 1622 (44%) 6578 3142 (47.8%) 10 262 4764 (46.4%) <0.001
Diabetes (Y) 3684 647 (17.6%) 6578 1298 (19.7%) 10 262 1945 (19%) 0.008
Hypercholesterolaemia (Y) 3684 1291 (35%) 6578 2678 (40.7%) 10 262 3969 (38.7%) <0.001
Polyvascular disease (Y)* 3684 530 (14.4%) 6578 1048 (15.9%) 10 262 1578 (15.4%) 0.038
Previous stroke or transient ischaemic attack (Y) 3684 101 (2.7%) 6578 172 (2.6%) 10 262 273 (2.7%) 0.704
Previous acute myocardial infarction (Y) 3684 265 (7.2%) 6578 570 (8.7%) 10 262 835 (8.1%) 0.010
Previous percutaneous coronary intervention (Y) 3684 194 (5.3%) 6578 482 (7.3%) 10 262 676 (6.6%) <0.001
Previous by-pass surgery (Y) 3684 20 (0.5%) 6578 85 (1.3%) 10 262 105 (1%) <0.001
History of peripheral arteriopathy (Y) 3684 153 (4.2%) 6578 276 (4.2%) 10 262 429 (4.2%) 0.957
Comorbidity (Y)† 3684 462 (12.5%) 6578 885 (13.5%) 10 262 1347 (13.1%) 0.191
Hepatopathy (Y) 3684 48 (1.3%) 6578 56 (0.9%) 10 262 104 (1%) 0.030
History of renal impairment (Y) 3684 185 (5%) 6578 320 (4.9%) 10 262 505 (4.9%) 0.741
History of heart failure (Y) 3684 272 (7.4%) 6578 583 (8.9%) 10 262 855 (8.3%) 0.009
Affected number of vessels ≥2 (Y) 3684 1275 (34.6%) 6578 2731 (41.5%) 10 262 4006 (39%) <0.001
No of treated vessels 3613 1.03±0.21 6516 1.06±0.26 10 129 1.05±0.25 <0.001
No of stents 3681 1.09±0.6 6563 1.21±0.68 10 244 1.16±0.65 <0.001
Drug-eluting stent (Y) 3684 572 (15.5%) 6578 2704 (41.1%) 10 262 3276 (31.9%) <0.001
DAPT score points 3684 1.20±1.20 6578 1.28±1.17 10 262 1.25±1.18 <0.001
Discharged home (Y) 3684 2233 (60.6%) 6578 3672 (55.8%) 10 262 5905 (57.5%) <0.001
Antiplatelet agent at discharge 3684 6578 10 262 <0.001
  Clopidogrel 3184 (86.4%) 4872 (74.1%) 8056 (78.5%)
  Prasugrel 278 (7.5%) 1102 (16.8%) 1380 (13.4%)
  Ticagrelor 222 (6%) 604 (9.2%) 826 (8%)
DAPT recommendation at discharge 3684 6578 10 262 <0.001
  1 month 875 (23.8%) 295 (4.5%) 1170 (11.4%)
  <12 months 385 (10.5%) 173 (2.6%) 558 (5.4%)
  ≥12 months 1522 (41.3%) 4732 (71.9%) 6254 (60.9%)
  Unknown 902 (24.5%) 1378 (20.9%) 2280 (22.2%)
*Polyvascular disease was defined as presence of at least two of the following conditions: previous myocardial infarction or percutaneous 
coronary or surgical revascularisation; history of peripheral arteriophaty; history of stroke or transient ischaemic attack. 
†Comorbidity was defined as presence of one of the following conditions: hepatophaty, history of renal impairment, history of heart failure.
DAPT, dual antiplatelet therapy. 
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the rate of drug-eluting stents implantation and the rate 
of prasugrel or ticagrelor also increased with time.
The overall rate of explicit DAPT recommendation for 
at least 12 months in the hospital discharge reports was 
51% (49–53) in 2010 and increased to 77% (75–79) in 
2015 but it was highly variable between hospitals (online 
supplementary figure 3).
Figure 2 shows the observed proportion of patients 
persisting with DAPT for at least 12 months at each time 
point and the interrupted time series model fitted after 
setting a 1 year lag period from publication to implemen-
tation of guidelines.
Table 3 shows results of the complete cases analysis 
(n=10 244) using interrupted time series logistic regres-
sion. Variables showing association with 12-month 
persistence on DAPT were two or more diseased vessels, 
higher number of stents implanted, receiving drug-
eluting stents, hypercholesterolaemia, a previous surgical 
procedure, taking prasugrel instead of clopidogrel and a 
recommendation of DAPT for a longer period at discharge 
from the PCI hospital. Autocorrelation was not signif-
icant. Guideline implementation had a positive effect 
on persistence: a 20% increase in the odds of 12-month 
persistence each quarter after a lag of 1 year since publica-
tion. The effect of drug-eluting stents was attenuated with 
time (OR for interaction: 0.96; 95% CI 0.94 to 0.97) while 
the effect of prescription was attenuated with time after 
guideline implementation (OR for the interaction 0.86, 
95% CI 0.79 to 0.94 for a recommendation of ≥12 months 
and 0.88, 95% CI 0.81 to 0.97 for an unknown recommen-
dation). The effect of implantation of drug-eluting stents 
and type of recommendation also varied between hospi-
tals (significant random slopes).
Results of sensitivity analyses, excluding patients with 
ischaemic or haemorrhagic events during follow-up, 
or excluding patients who were transferred to another 
centre after PCI were similar to the main analysis (online 
supplementary table 3S).
The interaction between drug-eluting stents and time 
can be seen in figure 3A. Because 12-month persistence 
increased with time in patients without drug-eluting 
stents, the effect of type of stent is attenuated with time. 
The interaction of the recommendation pattern with time 
and guideline implementation can be seen in figure 3B: 
12-month persistence increased with time mainly in the 
subgroups with shorter time specification in the discharge 
report and also in patients without a specific recommen-
dation, but this increase started after guideline imple-
mentation (1 year after publication). Figure 3C shows a 
substantial reduction in the variability between centres 
Figure 1 Patients flow. AMI, acute myocardial infarction; 
DAPT, dual antiplatelet therapy; PCI, percutaneous coronary 
intervention; ACO, anticoagulant therapy. 
Figure 2 Observed proportion of patients persisting 
with DAPT for at least 12 months at each quarter and 
the interrupted time series model fitted after setting a 
1 year lag period from publication to implementation of 
guidelines. DAPT, dual antiplatelet therapy. 
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mainly due to an increase in the proportion of 12-month 
persistence in patients attended in centres where the 
initial proportion was lower (significant random inter-
cept and slopes).
DIsCussIOn
According to published guidelines, all STEACS patients 
undergoing PCI without contraindication should be kept 
on DAPT for at least 12 months unless an event occurs that 
precludes continuing with this treatment. In this observa-
tional region-wide study, we have found an increase in the 
proportion of patients on-DAPT at 12 months from 58% 
to 73% in the period from 2010 to 2015, with an accel-
erated rate starting in the fourth quarter of 2013, 1 year 
after the publication of European guidelines.
We also found a high variability between hospitals in 
the adherence to guidelines when recommending DAPT 
for at least 12 months which leads to substantial differ-
ences between hospitals in the rate of patients persisting 
with the recommended DAPT. The progressive increase 
Table 3 Factors associated with a persistence of at least 
12 months as assessed with interrupted time series logistic 
regression model
Fixed effects OR 95% CI P value
Drug-eluting stent 1.90 1.50 to 2.40 <0.001
No of stents 1.22 1.13 to 1.32 <0.001
Antiplatelet agent 
at discharge (Ref. 
clopidogrel)
  Prasugrel 1.59 0.88 to 1.26 <0.001
  Ticagrelor 1.05 1.36 to 1.86 0.575
Recommendation at 
PCI hospital discharge 
(Ref. 1 month)
  <12 months 1.67 0.89 to 3.14 0.110
  ≥12 months 5.76 3.26 to 10.2 <0.001
  Unknown 2.25 0.84 to 6.01 0.107
Hypercholesterolaemia 1.19 1.08 to 1.31 <0.001
Previous by-pass 
surgery
1.85 1.09 to 3.14 0.023
Two or more treated 
vessels
1.21 1.10 to 1.33 <0.001
Drug-eluting stent * 
time (quarter)
0.96 0.94 to 0.97 <0.001
Guideline 
implementation
1.20 1.11 to 1.30 <0.001
Recommendation at 
PCI hospital discharge 
(Ref. 1 month) * time 
(quarter) * guideline 
implementation
  <12 months 0.90 0.79 to 1.04 0.144
  ≥12 months 0.86 0.79 to 0.94 <0.001
  Unknown 0.88 0.81 to 0.97 0.007
Random effects Variance 95% CI
Random—intercept 0.46 0.22 to 1.53
Random—slopes
Recommendation at PCI 
hospital discharge (Ref. 
1 month)
  <12 months 0.37 0.17 to 1.23
  ≥12 months 0.39 0.19 to 1.31
  Unknown 1.97 0.93 to 6.58
Drug-eluting stent 0.10 0.05 to 0.33
Adjusted Intracalss 
Correlation Coefficient
0.085
PCI, percutaneous coronary intervention. 
Figure 3 Temporal trend of interhospital variability in 
12-month DAPT recommendation at the PCI hospital, 
measured as the percentage of variance explained by the 
hospital level (intraclass correlation and 95% CI). Predicted 
probabilities of 12-month persistence by (A) drug-eluting 
stent, (B) recommendation pattern and (C) centre, over time. 
DAPT, dual antiplatelet therapy; PCI, percutaneous coronary 
intervention. 
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in the overall rate of 12-month persistence was accompa-
nied by a substantial reduction of interhospital variability.
Likelihood of patients persisting with DAPT for 
1 year is strongly related to the instructions given at the 
PCI hospital discharge, as we observed a lower rate of 
12-month persistence in patients receiving a discharge 
DAPT recommendation for <12 months. Although a 
causal direct relationship between the established recom-
mendation in the more specialised setting and the final 
prescription at the primary care setting cannot be stated 
on the basis of observational data, this finding suggests 
that prescribing physicians strongly rely on the first 
recommendation specified at the discharge report in the 
PCI hospital. Therefore, hospital cardiologists should be 
kept aware of their impact and encouraged to be clear 
and specific enough when providing DAPT time recom-
mendations in the discharge report form.
The recommendation in clinical guidelines of DAPT 
for at least 12 months following STEACS1 2 was based on 
the duration of follow-up of randomised clinical trials 
designed for other purposes11–13 and, although a 12-month 
treatment seemed reasonable,14 no randomised studies 
had been performed within the study period aimed 
specifically at comparing 12-month DAPT with shorter 
periods in STEACS patients receiving PCI and thus this 
recommendation might well be seen as somehow arbi-
trary by some prescribers.
In 2015, the need for long-term DAPT was reinforced 
by the recommendation of extended DAPT beyond 
12 months in patients with ACS receiving drug-eluting 
stents,15–17 but still safety concerns might induce some 
prescribers to be reluctant to prolong DAPT, especially in 
patients with higher complexity.18 Safety concerns might 
also explain the high proportion of discharge reports 
with non-specified DAPT period, which deserved special 
attention in our analyses. Cardiologists might be reluctant 
to prescribe a specific duration of DAPT maybe fearing 
about the emergency of events that increase the haemor-
rhagic risk at some point after discharge, thus relying on 
the follow-up that will be made at the ambulatory setting. 
Our results showing a high degree of persistence for 
patients without a specification of DAPT time point out 
to the fact that this decision is not necessarily ‘incorrect’, 
and that health providers coming later in the process of 
care are probably doing their job.
We might wonder whether the observed high variability 
between hospitals in the instructions provided about 
DAPT duration actually reflects suboptimal quality of 
care or confusion in the interpretation of international 
guidelines. In fact, although 2012 European Society of 
Cardiology guidelines state that DAPT must be continued 
for 12 months after STEACS with a class of recommen-
dation I, the level of evidence was established as C.1 
Thus, there was general agreement that a minimum of 
12 months of DAPT is likely to be beneficial but based 
only on a consensus of experts or observational studies. 
Moreover, it is literally stated that the given recommenda-
tion on DAPT duration should be ‘with a strict minimum 
of 1 month for patients receiving BMS and 6 months for 
patients receiving DES’, with class IC and IIb, respectively. 
These messages, which ultimately reflected the lack of 
clinical trials aimed to answer the specific question about 
DAPT duration, could have induced a perception of arbi-
trariness leading to variability in clinical practice.
In fact, the optimal duration of DAPT has not yet been 
totally established in more contemporary clinical trials. 
The most recent randomised clinical trial conducted 
in patients with STEACS aimed to assess the question 
of 12-month vs a 6-month DAPT duration, showed that 
6-month DAPT duration after primary PCI was non-in-
ferior to 12-month duration to prevent major cardiovas-
cular events.19 In another trial in the context of ACS, 12 
months or longer DAPT duration versus 6 months was 
not associated with lower major cardiovascular events and 
total mortality.20
Regardless the level of the evidence, one would expect 
that a class I recommendation should be uniformly 
followed by clinicians. Moreover, as patient characteristics 
did not substantially differed across hospitals, we should 
expect a lower variability between hospitals. A large vari-
ation in individual country practices concerning the 
pattern of DAPT duration after ACS has been described, 
suggesting that local systems are strong drivers of DAPT 
duration.21 These findings may imply that there is still 
room for improvement in the quality of care of STEACS 
patients and that quality improvement programmes, 
whose efficacy and cost-effectiveness are still under eval-
uation, could be useful to reduce variability in clinical 
practice.22 This is of prime importance in the context of 
the prescription of DAPT duration after ACS in which the 
clinician-driven variability in prescription patterns adds 
to the different levels patients’ adherence.21
Higher atherosclerotic burden and increased ischaemic 
risk was associated to better persistence with DAPT. The 
need for 12-month DAPT schedules in patients treated 
with drug-eluting stents is clearly perceived by physi-
cians but the magnitude of this association varies largely 
between hospitals. This means that, even in clear indica-
tions, there are different levels of adoption of emerging 
clinical recommendations in hospitals belonging to the 
same AMI network.
It is also apparent from our data that the speed of adop-
tion of clinical guidelines is different among hospitals and 
that an acceptable and generalised level of adherence 
is only reached after 2 years of implementation. Similar 
trends have been found in other contexts and earlier 
periods23–28 reporting DAPT use between 60% and 80% 
at discharge and between 25% and 75% at 1 year. In this 
sense, together with other quality improvement initia-
tives, the use of population-based registries to provide 
audit and feedback could be useful to promote quicker 
and smoother adoption of clinical practice guidelines.29
There are a number of assumptions that might be ques-
tionable: a number of factors have been described to 
contribute to underprescription.30 The complete process 
of care and the definite prescription at the ambulatory 
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setting is poorly known for individual patients and has 
not been considered in this study. Changes in treatment 
prescription might be justified by the patients’ varying 
conditions during follow-up. We assume that hospital 
recommendation influences final prescription, and conse-
quently, final adherence to guidelines, but it can also be 
that both ‘prescribers’ facing the same patient share the 
same criteria for prescription. That is, the hospital cardi-
ologist might have decided to recommend DAPT for a 
shorter period to an elderly patient with other comor-
bidities and suboptimal quality of life due to mild diges-
tive symptoms, even if her objective bleeding risk is not 
high; similarly, the primary physician or the cardiologist 
at the primary care setting might have also decided to be 
less aggressive for the same reasons, even without being 
influenced by the recommendation of the first prescriber. 
This would probably explain a large amount of the strong 
relationship between hospital recommendation and 
pharmacy dispensation. Moreover, although effects were 
adjusted for patient characteristics and vascular events 
during follow-up, there might be other unmeasured 
reasons for deciding on a shorter DAPT period facing an 
individual patient.
In addition, the recommendation at PCI hospital 
discharge may not coincide with the final hospital 
prescription in patients derived to another reference 
hospital after PCI. However, results of sensitivity analyses 
excluding these patients did not differ substantially from 
the results of the main analyses.
The study was aimed to ascertain influence of guidelines 
on hospital recommendation and its impact on patients’ 
persistence with DAPT. The impact of persistence on clin-
ically relevant results will be assessed in another article. 
Similarly, the study was not specifically aimed at a deep 
assessment of determinants of adherence. This requires a 
detailed examination of the social context and a detailed 
assessment of individual psychological factors.31
COnClusIOn
The study shows that 12-month DAPT persistence in 
revascularised patients with STEACS in Catalonia (Spain) 
has substantially increased between years 2010 and 2015 
especially since 1 year after the publication of European 
guidelines in 2012. Guideline implementation was also 
followed by a substantial decrease in variability between 
centres. We have shown that instructions given at the PCI 
hospital discharge are strongly associated with persistence. 
Thus, establishing common and rational prescribing 
criteria between hospitals in the STEACS network may 
favour patients persistence with scheduled prescriptions 
and also reduce variability in clinicians’ practices.
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